Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent and selective proline derived dipeptidyl peptidase IV inhibitors.
Edmondson SD, Mastracchio A, Beconi M, Colwell LF Jr, Habulihaz B, He H, Kumar S, Leiting B, Lyons KA, Mao A, Marsilio F, Patel RA, Wu JK, Zhu L, Thornberry NA, Weber AE, Parmee ER. Edmondson SD, et al. Among authors: mao a. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5151-5. doi: 10.1016/j.bmcl.2004.07.056. Bioorg Med Chem Lett. 2004. PMID: 15380217
Structure and Ligand Based Virtual Screening and MPO Topological Analysis of Triazolo Thiadiazepine-fused Coumarin Derivatives as Anti-Parkinson Drug Candidates.
Pereira AMG, de Oliveira VM, da Rocha MN, Roberto CHA, Cajazeiras FFM, Guedes JM, Marinho MM, Teixeira AMR, Marinho ES, de Lima-Neto P, Dos Santos HS. Pereira AMG, et al. Mol Biotechnol. 2024 Jun 4. doi: 10.1007/s12033-024-01200-y. Online ahead of print. Mol Biotechnol. 2024. PMID: 38834896
Parkinson's disease (PD) is a debilitating condition that can cause locomotor problems in affected patients, such as tremors and body rigidity. PD therapy often includes the use of monoamine oxidase B (MAOB) inhibitors, particularly phenylhalogen compounds and couma …
Parkinson's disease (PD) is a debilitating condition that can cause locomotor problems in affected patients, such as tremors and body rigidi …
Tyrosinase deficiency impairs social novelty preference in mice.
Aizawa S, Yamamuro Y. Aizawa S, et al. Neuroreport. 2024 May 30. doi: 10.1097/WNR.0000000000002055. Online ahead of print. Neuroreport. 2024. PMID: 38829918
We also found that the hippocampal expression of genes involved in catecholamine metabolism, such as monoamine oxidase A and catechol-O-methyltransferase, were significantly decreased in tyrosinase-deficient B10-c mice. ...
We also found that the hippocampal expression of genes involved in catecholamine metabolism, such as monoamine oxidase A and c …
Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives.
Gucký A, Hamuľaková S. Gucký A, et al. CNS Drugs. 2024 Jun 3. doi: 10.1007/s40263-024-01093-0. Online ahead of print. CNS Drugs. 2024. PMID: 38829443 Review.
Various coumarin derivatives match this description and apart from being able to chelate metal ions, they exhibit the capacity to inhibit cholinesterases (ChEs) and monoamine oxidase B (MAO-B) while also possessing antioxidant, anti-inflammatory, and numerous other …
Various coumarin derivatives match this description and apart from being able to chelate metal ions, they exhibit the capacity to inhibit ch …
Computational identification of potential acetylcholinesterase (AChE) and monoamine oxidase-B inhibitors from Vitis vinifera: a case study of Alzheimer's disease (AD).
Sofela SO, Ibrahim A, Ogbodo UC, Bodun DS, Nwankwo DO, Mafimisebi M, Abdulrasheed B, Balogun T, Opeyemi I. Sofela SO, et al. In Silico Pharmacol. 2024 May 31;12(1):49. doi: 10.1007/s40203-024-00214-3. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38828442
At the same time, the currently available anti-cholinesterase (AChE) and monoamine oxidase-B (MAO-B) for the treatment of AD can only improve the clinical symptoms while the recently approved immunotherapy agent "remains questionable. ...
At the same time, the currently available anti-cholinesterase (AChE) and monoamine oxidase-B (MAO-B) for the treatment of AD c …
Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms.
Rakoczy RJ, Runge GN, Sen AK, Sandoval O, Wells HG, Nguyen Q, Roberts BR, Sciortino JH, Gibbons WJ Jr, Friedberg LM, Jones JA, McMurray MS. Rakoczy RJ, et al. Br J Pharmacol. 2024 Jun 2. doi: 10.1111/bph.16466. Online ahead of print. Br J Pharmacol. 2024. PMID: 38825326
KEY RESULTS: In vitro enzyme kinetics assays found that all compounds had nearly identical rates of dephosphorylation via alkaline phosphatase and metabolism by monoamine oxidase. Further, we found that only the dephosphorylated products of baeocystin and norbaeocys …
KEY RESULTS: In vitro enzyme kinetics assays found that all compounds had nearly identical rates of dephosphorylation via alkaline phosphata …
26,223 results
You have reached the last available page of results. Please see the User Guide for more information.